This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Solid Biosciences stock | $3.23

Own Solid Biosciences stock in just a few minutes.

Posted

Fact checked

Solid Biosciences Inc is a drug manufacturers-specialty & generic business based in the US. Solid Biosciences shares (SLDB) are listed on the NASDAQ and all prices are listed in US Dollars. Solid Biosciences employs 121 staff and has a market cap (total outstanding shares value) of USD$211.6 million.

How to buy shares in Solid Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Solid Biosciences. Find the stock by name or ticker symbol: SLDB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Solid Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$3.23, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Solid Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Solid Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Solid Biosciences share price

Use our graph to track the performance of SLDB stocks over time.

Solid Biosciences shares at a glance

Information last updated 2020-12-03.
Latest market close USD$3.23
52-week range USD$1.93 - USD$5.58
50-day moving average USD$3.3721
200-day moving average USD$2.9742
Wall St. target price USD$4.7
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.796

Buy Solid Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Solid Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Solid Biosciences price performance over time

Historical closes compared with the close of $3.23 from 2020-11-16

1 week (2020-11-25) 2.87%
1 month (2020-11-06) 0.31%
3 months (2020-09-04) 49.54%
6 months (2020-06-04) 9.86%
1 year (2019-12-04) -27.74%
2 years (2018-12-04) -88.66%
3 years (2017-12-02) N/A
5 years (2015-12-02) N/A

Solid Biosciences financials

Gross profit TTM USD$0
Return on assets TTM -71.05%
Return on equity TTM -151.1%
Profit margin 0%
Book value $0.481
Market capitalisation USD$211.6 million

TTM: trailing 12 months

Shorting Solid Biosciences shares

There are currently 3.2 million Solid Biosciences shares held short by investors – that's known as Solid Biosciences's "short interest". This figure is 1% down from 3.2 million last month.

There are a few different ways that this level of interest in shorting Solid Biosciences shares can be evaluated.

Solid Biosciences's "short interest ratio" (SIR)

Solid Biosciences's "short interest ratio" (SIR) is the quantity of Solid Biosciences shares currently shorted divided by the average quantity of Solid Biosciences shares traded daily (recently around 920770.77363897). Solid Biosciences's SIR currently stands at 3.49. In other words for every 100,000 Solid Biosciences shares traded daily on the market, roughly 3490 shares are currently held short.

However Solid Biosciences's short interest can also be evaluated against the total number of Solid Biosciences shares, or, against the total number of tradable Solid Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Solid Biosciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Solid Biosciences shares in existence, roughly 50 shares are currently held short) or 0.0827% of the tradable shares (for every 100,000 tradable Solid Biosciences shares, roughly 83 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Solid Biosciences.

Find out more about how you can short Solid Biosciences stock.

Solid Biosciences share dividends

We're not expecting Solid Biosciences to pay a dividend over the next 12 months.

Solid Biosciences share price volatility

Over the last 12 months, Solid Biosciences's shares have ranged in value from as little as $1.93 up to $5.58. A popular way to gauge a stock's volatility is its "beta".

SLDB.US volatility(beta: 0.85)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Solid Biosciences's is 0.8534. This would suggest that Solid Biosciences's shares are less volatile than average (for this exchange).

Solid Biosciences overview

Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to derive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site